World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025

D-Index & Metrics

Best Scientists

D-Index
168
Citations
133379
World Ranking
937
National Ranking
555

Medicine

D-Index
173
Citations
140220
World Ranking
469
National Ranking
277

Research.com Recognitions

  • 2025 - Research.com Best Scientists Award
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Pasi A. Jänne is affiliated with Harvard University in the United States and has contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research focuses significantly on pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and radiology, nuclear medicine, and imaging.

The scientist's work covers a range of topics including lung cancer treatments and mutations, colorectal cancer treatments and studies, lung cancer research studies, cancer genomics and diagnostics, HER2/EGFR in cancer research, lung cancer diagnosis and treatment, and cancer immunotherapy and biomarkers.

Frequent publication venues for Pasi A. Jänne include the Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research, and Clinical Cancer Research.

Frequent co-authors are James Chih-Hsin Yang, Lynette M. Sholl, Mark M. Awad, Enriqueta Felip, and David Planchard.

Notable recent papers authored or co-authored by Pasi A. Jänne include:

  • Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation, 2022, New England Journal of Medicine
  • Kinase drug discovery 20 years after imatinib: progress and future directions, 2021, Nature Reviews Drug Discovery
  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer, 2021, New England Journal of Medicine
  • Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC, 2023, New England Journal of Medicine
  • Overcoming therapy resistance in EGFR-mutant lung cancer, 2021, Nature Cancer

Pasi A. Jänne is a member of the Association of American Physicians.

Best Publications

  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

    J. Guillermo Paez;Pasi A. Jänne;Pasi A. Jänne;Jeffrey C. Lee;Sean Tracy

  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

    Susumu Kobayashi;Titus J. Boggon;Tajhal Dayaram;Pasi A. Jänne

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

    David A. Eberhard;Bruce E. Johnson;Lukas C. Amler;Audrey D. Goddard

  • Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

    Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Kenneth S Thress;Cloud P Paweletz;Enriqueta Felip;Byoung Chul Cho

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

    Esra A. Akbay;Esra A. Akbay;Shohei Koyama;Julian Carretero;Abigail Altabef;Abigail Altabef

  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

    Alexa B. Turke;Kreshnik Zejnullahu;Yi Long Wu;Youngchul Song

  • LKB1 modulates lung cancer differentiation and metastasis

    Hongbin Ji;Matthew R. Ramsey;D. Neil Hayes;Cheng Fan

  • The quest to overcome resistance to EGFR-targeted therapies in cancer

    Curtis R Chong;Pasi A Jänne;Pasi A Jänne

  • Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

    Wenjun Zhou;Dalia Ercan;Liang Chen;Cai-Hong Yun

  • EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

    Jussi P. Koivunen;Craig Mermel;Kreshnik Zejnullahu;Carly Murphy

  • Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

    Doron Lipson;Marzia Capelletti;Roman Yelensky;Geoff Otto

Frequent Co-Authors

Bruce E. Johnson
Bruce E. Johnson Harvard University
Kwok-Kin Wong
Kwok-Kin Wong New York University
Matthew Meyerson
Matthew Meyerson Harvard University
Cloud P. Paweletz
Cloud P. Paweletz Harvard University
Lynette M. Sholl
Lynette M. Sholl Brigham and Women's Hospital
Nathanael S. Gray
Nathanael S. Gray Stanford University
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Neal I. Lindeman
Neal I. Lindeman Brigham and Women's Hospital
Levi A. Garraway
Levi A. Garraway Roche (United States)
Mark M. Awad
Mark M. Awad Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online medical degrees can offer flexibility and quicker entry into healthcare careers. Many students are searching for fast-tracked or affordable programs to meet workforce demands while balancing other commitments.

For nurses aiming to advance their qualifications, the fastest dnp program options provide an accelerated path to a Doctor of Nursing Practice. If cost is a concern, consider the cheapest online dnp programs, which combine quality education with affordability.

Those looking for a faster entry point into nursing should look into the 6 month lpn program online. These programs can help students become Licensed Practical Nurses in a significantly shorter time.

Mental health is another growing field with strong career opportunities. The fastest pmhnp program allows registered nurses to quickly specialize as Psychiatric Mental Health Nurse Practitioners.

Whether you’re seeking advanced practice, affordability, or a fast-track to a healthcare role, online degrees can open doors to diverse medical career pathways.

Best Scientists Citing Pasi A. Jänne

Trending Scientists